TOFAJAK
Tofajak is a oral targeted therapy you can take at home.
Tofajak may be able to treat adults with moderately to severely active rheumatoid arthritis, moderate to severe ulcerative colitis and active psoriatic arthritis.
Tofajak is approved to treat children with active Polyarticular juvenile idiopathic arthritis.
Stretching your way to a pain free life.
How to take TOFAJAK
Tofajak is taken as tablets of 5mg that can be taken with or food. The usual dose is two tablets a day. It’s half-life is approximately 3 hours.
It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifiying anthirheumatic drugs (DMARDS), when methotrexate alone is not sufficient.
Interview By Dr Javaid Mehmood Malik
Interview By Dr. Ahmed
INDICATIONS & DOSING
 Rheumatoid Arthritis
- Indicated for moderate-to-severe active rheumatoid arthritis (RA) in adults with an inadequate response or intolerance to methotrexate; may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs
  Tofajak: 5 mg BD
 Psoriatic Arthritis
- Indicated for active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs
- Recommended dose in combination with nonbiologic DMARDs.
 Tofajak: 5 mg BD
 Ulcerative Colitis
- Indicated for adults with moderately to severely active ulcerative colitis (UC)
 Tofajak Induction
- Two (2) 5mg tablets BD for at least 8 weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response
- If needed, continue two (2) 5mg tablets BD for maximum of 16 weeks; discontinue after 16 weeks if adequate therapeutic benefit not achieved
 Maintenance
- 5 mg BD; may consider two (2) 5 mg tablets BD (limited to shorter duration) in patients with loss of response during maintenance treatment
- Use the lowest effective dose needed to maintain response.
Â
BENEFITS
The administration route of JAK inhibitors is oral, not a subcutaneous/intravenous injection.
Considering the potential harmful effects of oral steroids, the concomitant use of an oral steroid is not necessary for the treatment of RA using JAK inhibitors, and we should use the lowest possible dose of oral steroids for the shortest time as in the EULAR recommendation.
With each wave of research, Spherix Global Insights (a hyper-focused market intelligence firm) has found that the JAK inhibitor class has captured a greater portion of share in all lines therapy over the past year and a half.
Just Take
Tofajak
No Need For subcutaneous
Injection
No Need For Intravenous
Injection
No Need For Cold Storage
any More
